Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Repare Therapeutics Inc (RPTX)

Repare Therapeutics Inc (RPTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 584,002
  • Shares Outstanding, K 41,894
  • Annual Sales, $ 7,600 K
  • Annual Income, $ -106,910 K
  • 60-Month Beta -0.16
  • Price/Sales 77.12
  • Price/Cash Flow N/A
  • Price/Book 2.26
Trade RPTX with:

Options Overview Details

View History
  • Implied Volatility 78.80% ( -12.08%)
  • Historical Volatility 120.54%
  • IV Percentile 12%
  • IV Rank 14.57%
  • IV High 165.97% on 05/06/22
  • IV Low 63.93% on 04/21/22
  • Put/Call Vol Ratio 4.27
  • Today's Volume 58
  • Volume Avg (30-Day) 665
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 3,512
  • Open Int (30-Day) 5,014

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.86
  • Number of Estimates 5
  • High Estimate -0.80
  • Low Estimate -0.91
  • Prior Year -0.71
  • Growth Rate Est. (year over year) -21.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.68 +30.52%
on 06/02/22
15.11 -7.74%
on 06/08/22
+5.19 (+59.31%)
since 06/01/22
3-Month
8.06 +72.85%
on 05/20/22
15.16 -8.05%
on 04/04/22
-0.56 (-3.86%)
since 04/01/22
52-Week
8.06 +72.85%
on 05/20/22
35.75 -61.01%
on 08/10/21
-17.19 (-55.22%)
since 07/01/21

Most Recent Stories

More News
Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain...

MRTX : 71.18 (+6.03%)
BBC : 22.34 (+3.45%)
KZR : 9.29 (+12.33%)
RPTX : 13.94 (-0.36%)
DAWN : 19.95 (+11.45%)
LYEL : 5.99 (-8.13%)
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate...

RPTX : 13.94 (-0.36%)
Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug

Repare Therapeutics (RPTX) signs a licensing agreement with Roche (RHHBY) to develop its lead candidate for solid tumor indications.

RHHBY : 42.0100 (+0.72%)
AGLE : 0.5101 (+0.99%)
SESN : 0.7989 (-1.42%)
RPTX : 13.94 (-0.36%)
Why Repare Therapeutics Stock Is Skyrocketing Today

The company just announced a major collaboration with multinational pharmaceutical giant Roche.

RPTX : 13.94 (-0.36%)
RHHBY : 42.0100 (+0.72%)
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has entered into a worldwide license and collaboration...

RPTX : 13.94 (-0.36%)
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate...

RPTX : 13.94 (-0.36%)
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

RPTX : 13.94 (-0.36%)
CDXC : 1.6700 (unch)
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31,...

RPTX : 13.94 (-0.36%)
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

GBT : 32.80 (+2.66%)
RPTX : 13.94 (-0.36%)
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that preclinical data demonstrating inhibition of CCNE1-amplified...

RPTX : 13.94 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare...

See More

Key Turning Points

3rd Resistance Point 14.84
2nd Resistance Point 14.46
1st Resistance Point 14.20
Last Price 13.94
1st Support Level 13.56
2nd Support Level 13.18
3rd Support Level 12.92

See More

52-Week High 35.75
Fibonacci 61.8% 25.17
Fibonacci 50% 21.91
Fibonacci 38.2% 18.64
Last Price 13.94
52-Week Low 8.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar